Unveiling immune targets via TriStageHLA: high-throughput screening of peptide presentation, peptide–HLA binding, and immunogenicity

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

High-throughput screening of HLA class I epitopes underpins neoantigen vaccine design, T cell therapies, and pathogen immune monitoring, yet proteome-scale prioritization remains challenging under severe class imbalance. We present TriStageHLA, a compact three-stage framework that decomposes epitope discovery into peptide-only screening (PRE), allele-specific binding/presentation prediction (BIND), and immunogenicity prediction (IM). PRE performs early pruning via a LoRA-adapted ESM-2 classifier; BIND integrates quantitative binding affinity and eluted ligand data with a dual-branch architecture combining global cross-attention and local motif extraction; IM is fine-tuned on curated human T-cell assay data with a decoupled LoRA head. Trained on IEDB-derived datasets with per-allele balancing and allele-discordant supervision, TriStageHLA-BIND achieves AUROC of 96.2% and AUPRC of 95.2% on combined BA/EL evaluation, while TriStageHLA-IM reaches AUROC of 81.4% and AUPRC of 73.8% on held-out immunogenicity data, improving over the strongest immunogenicity baselines ImmuneApp (70.7% / 63.6%) and BigMHC-IM (60.1% / 51.5%). With substantially fewer trainable parameters than prior models, TriStageHLA enables efficient, calibrated epitope prioritization across binding, presentation, and immunogenicity. Code and pretrained weights are available at https://github.com/SkywalkerLuke/TriStageHLA .

Article activity feed